Here, six house and techno artists provide a look into what it’s like being a tastemaker spinning at Time Warp. They discuss their favorite memories, why the event is special to them and more.

Lilly Endowment Inc. is supporting the renewal of Indiana K-12 educators through its 2025 Teacher Creativity Fellowship Program. The Endowment has approved grants of up to $15,000 each to 129 ...

Instead, history repeated itself ... Obvious industry leaders include Intuitive Surgical and Eli Lilly. Lilly returned 32% last year, while Intuitive returned 55%. Another way to play the sector ...

Google Deepmind co-founder Demis Hassabis talks to FT editor Roula Khalaf about the real world healthcare applications of AI and how his ground-breaking work on the structure of proteins could acceler ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

Eli Lilly, which first broke ground on its state-of-the-art Concord manufacturing facility ... professor of politics and history at Catawba College, who spoke to the crowd about the 2024 elections.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

During the last three months, 7 analysts shared their evaluations of Eli Lilly LLY, revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings, showcasing ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...